Maxime Louet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maxime Louet has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Anthony Feral
IBMM (Institut des Biomolécules Max Mousseron), Amino Acids, Peptides and Proteins department, Université de Montpellier, CNRS, Ecole Nationale Supérieure de Chimie de Montpellier
2 shared publications - Jérôme Azé
LIRMM, Laboratory of Computer Science, Robotics and Microelectronics in Montpellier, CNRS Montpellier University Montpellier France
2 shared publications - Krzysztof Rogowski
Institute of Human Genetics
2 shared publications - Laurent Gavara
Institut des Biomolécules Max Mousseron, Univ Montpellier, CNRS, ENSCM, Montpellier, France
2 shared publications - Lubomir L. Vezenkov
IBMM Université Montpellier, CNRS, ENSCM Montpellier France
2 shared publications - Muriel Amblard
IBMM UMR5247 Univ. Montpellier CNRS ENSCM Montpellier France
2 shared publications
Latest Publications
- 30 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Étude à l'échelle moléculaire des protéines-G couplées à leurs récepteurs.
Les protéines-G hétérotrimériques, constituées des sous-unités α, β et γ, sont les premières actrices de la transduction du signal en interagissant directement avec les Récepteurs Couplés aux protéines-G (RCPG). Les protéines-G ont la capacité de lier soit une molécule de GDP lorsqu'elles sont inactives, soit une molécule de GTP quand elles sont activées par un RCPG. Cet échange de nucléotide va conduire à la dissociation de l'hétérotrimère avec d'une part la sous-unité α seule, et d'autre part le complexe βγ. Chacune de ces entités va ensuite propager le signal dans le compartiment intracellulaire. Les travaux effectués au cours de cette thèse ont pour but de mieux comprendre la dynamique des protéines-G hétérotrimériques et de leurs récepteurs par des techniques de mécanique moléculaire incluant la Dynamique Moléculaire (DM) et l'Analyse de Modes Normaux (AMN). Dans un premier temps une AMN nous a permis de décrire les possibles mouvements de larges amplitudes des protéine-G. Nous avons à l'occasion de cette étude mis au point une méthode de sélection de Modes Normaux (MN) pertinents que nous avons appelés modes représentatifs. Nous avons également développé une méthode d'extraction de ligand (ici le GDP) le long de ces MN. Ceci nous a permis de montrer qu'un mouvement concerté de toute la sous-unité α pouvait permettre l'ouverture de la poche et la sortie du GDP. Dans un deuxième temps, nous avons affiné nos résultats en reconstruisant des profils d'énergie libre le long de plusieurs chemins de sortie possibles pour le GDP. Ainsi nous avons pu proposer un mécanisme fin de sortie du ligand et plusieurs résidus clés impliqués dans cette sortie. Nous avons également étudié le processus de dissociation de l'hétérotrimère par la technique de la Dynamique Moléculaire Dirigée. Il a été possible, à l'issue de cette étude, de proposer un mécanisme à l'échelle moléculaire de la séparation des sous-unités α et βγ. Pour finir, nous avons également étudié le macro-complexe RCPG : protéine-G. Deux études traitent des mécanismes d'activation et de couplage des protéines-G à son récepteur. Nous avons notamment montré que l'hétérotrimère de protéine-G contraint très fortement les mouvements du récepteur. Un mouvement très largement retrouvé dans le complexe ainsi que dans plusieurs autres RCPGs dont les structures sont connues a été proposé comme étant le mouvement d'activation des RCPG une fois complexés à leurs protéines partenaires.
- 30 March 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Étude à l'échelle moléculaire des protéines-G couplées à leurs récepteurs.
Les protéines-G hétérotrimériques, constituées des sous-unités α, β et γ, sont les premières actrices de la transduction du signal en interagissant directement avec les Récepteurs Couplés aux protéines-G (RCPG). Les protéines-G ont la capacité de lier soit une molécule de GDP lorsqu'elles sont inactives, soit une molécule de GTP quand elles sont activées par un RCPG. Cet échange de nucléotide va conduire à la dissociation de l'hétérotrimère avec d'une part la sous-unité α seule, et d'autre part le complexe βγ. Chacune de ces entités va ensuite propager le signal dans le compartiment intracellulaire. Les travaux effectués au cours de cette thèse ont pour but de mieux comprendre la dynamique des protéines-G hétérotrimériques et de leurs récepteurs par des techniques de mécanique moléculaire incluant la Dynamique Moléculaire (DM) et l'Analyse de Modes Normaux (AMN). Dans un premier temps une AMN nous a permis de décrire les possibles mouvements de larges amplitudes des protéine-G. Nous avons à l'occasion de cette étude mis au point une méthode de sélection de Modes Normaux (MN) pertinents que nous avons appelés modes représentatifs. Nous avons également développé une méthode d'extraction de ligand (ici le GDP) le long de ces MN. Ceci nous a permis de montrer qu'un mouvement concerté de toute la sous-unité α pouvait permettre l'ouverture de la poche et la sortie du GDP. Dans un deuxième temps, nous avons affiné nos résultats en reconstruisant des profils d'énergie libre le long de plusieurs chemins de sortie possibles pour le GDP. Ainsi nous avons pu proposer un mécanisme fin de sortie du ligand et plusieurs résidus clés impliqués dans cette sortie. Nous avons également étudié le processus de dissociation de l'hétérotrimère par la technique de la Dynamique Moléculaire Dirigée. Il a été possible, à l'issue de cette étude, de proposer un mécanisme à l'échelle moléculaire de la séparation des sous-unités α et βγ. Pour finir, nous avons également étudié le macro-complexe RCPG : protéine-G. Deux études traitent des mécanismes d'activation et de couplage des protéines-G à son récepteur. Nous avons notamment montré que l'hétérotrimère de protéine-G contraint très fortement les mouvements du récepteur. Un mouvement très largement retrouvé dans le complexe ainsi que dans plusieurs autres RCPGs dont les structures sont connues a été proposé comme étant le mouvement d'activation des RCPG une fois complexés à leurs protéines partenaires.
- Open Access
- 31 December 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (1)
Peptide-based covalent inhibitor of tubulin detyrosination promotes mesenchymal-to-epithelial transition in lung cancer cells
Detyrosination is a reversible posttranslational modification specific to α-tubulin, which has been implicated in cancer progression and invasiveness by promoting epithelial-to-mesenchymal transition. The members of the vasohibin family, VASH1 and VASH2, were previously identified as the first class of enzymes involved in catalyzing this modification. Here, we report the development of a covalent VASH inhibitor, which is characterized by high specificity and low toxicity. By combining the use of a new compound with molecular approaches in lung cancer cell lines, we find that tubulin detyrosination plays an important role in the maintenance of mesenchymal properties. We show that in the absence of VASH activity, collective cell migration and 3D spheroid formation are severely compromised. Moreover, we demonstrate that the observed phenotypes are caused by the accumulation of the important epithelial marker E-cadherin with simultaneous reduction in mesenchymal markers N-cadherin and vimentin. Taken together, our study establishes tubulin detyrosination as a promising target for the future development of anticancer treatment.
- 31 December 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (1)
Open AccessPeptide-based covalent inhibitor of tubulin detyrosination promotes mesenchymal-to-epithelial transition in lung cancer cells
Detyrosination is a reversible posttranslational modification specific to α-tubulin, which has been implicated in cancer progression and invasiveness by promoting epithelial-to-mesenchymal transition. The members of the vasohibin family, VASH1 and VASH2, were previously identified as the first class of enzymes involved in catalyzing this modification. Here, we report the development of a covalent VASH inhibitor, which is characterized by high specificity and low toxicity. By combining the use of a new compound with molecular approaches in lung cancer cell lines, we find that tubulin detyrosination plays an important role in the maintenance of mesenchymal properties. We show that in the absence of VASH activity, collective cell migration and 3D spheroid formation are severely compromised. Moreover, we demonstrate that the observed phenotypes are caused by the accumulation of the important epithelial marker E-cadherin with simultaneous reduction in mesenchymal markers N-cadherin and vimentin. Taken together, our study establishes tubulin detyrosination as a promising target for the future development of anticancer treatment.
- 25 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (17) , 18335-18355
Development of Low-Nanomolar Covalent Epoxide Inhibitors of Tubulin Detyrosinating Enzymes VASH1&2
The development of small molecule inhibitors targeting the set of microtubules' post-translational modifications, also known as the "tubulin code", remains an underexplored area in medicinal chemistry. The recent discovery of the VASH1 and VASH2 enzymes, which are responsible for tubulin detyrosination─a modification associated with neurodegeneration and cancer─prompted us to develop new molecules that inhibit their activity. In this study, we conducted the first QSAR analysis of VASH proteases. Through rational substrate-based design, we identified our lead compound, LV87, as a potent epoxide-based covalent inhibitor of tubulin detyrosination in cellulo. Specificity assessments against other cysteine proteases and incubations with nonspecific nucleophiles demonstrated that LV87 selectively targets VASH1/2. Additionally, safety data, serum, and microsome stability tests support the notion that LV87 is a selective and potent inhibitor of tubulin detyrosination, paving the way for further optimization and applications.
- 25 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (17) , 18335-18355
Development of Low-Nanomolar Covalent Epoxide Inhibitors of Tubulin Detyrosinating Enzymes VASH1&2
The development of small molecule inhibitors targeting the set of microtubules' post-translational modifications, also known as the "tubulin code", remains an underexplored area in medicinal chemistry. The recent discovery of the VASH1 and VASH2 enzymes, which are responsible for tubulin detyrosination─a modification associated with neurodegeneration and cancer─prompted us to develop new molecules that inhibit their activity. In this study, we conducted the first QSAR analysis of VASH proteases. Through rational substrate-based design, we identified our lead compound, LV87, as a potent epoxide-based covalent inhibitor of tubulin detyrosination in cellulo. Specificity assessments against other cysteine proteases and incubations with nonspecific nucleophiles demonstrated that LV87 selectively targets VASH1/2. Additionally, safety data, serum, and microsome stability tests support the notion that LV87 is a selective and potent inhibitor of tubulin detyrosination, paving the way for further optimization and applications.
- 24 April 2025
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 65 (9) , 4630-4642
Unveiling G-Protein-Coupled Receptor Conformational Dynamics via Metadynamics Simulations and Markov State Models
The dynamic character of G-protein-coupled receptors (GPCRs) is essential in their functionality as signal transducers. However, the molecular details of how ligands affect this conformational repertoire to steer intracellular signaling pathways remain elusive. To address this question, we present a generally applicable protocol that combines metadynamics simulations and Markov state modeling to compute the free energy landscape of the growth hormone secretagogue receptor (GHSR-1a), a prototypical class A GPCR, in its apo state and bound to pharmacologically distinct ligands. Consistent with the current multistate model of GPCR activity, we found that GHSR-1a populates multiple metastable states whose energies and transition probabilities change depending on the bound ligand. We identified intermediate states that have not yet been described by experimental structures and shed light on the molecular differences between basal and agonist-induced GHSR-1a activation. Our results are not only compatible with previously reported experimental data, but they capture the equilibria governing GHSR-1a activation in unprecedented detail. Due to its applicability to all class A GPCRs, our protocol is a valuable tool for the development of pharmaceuticals targeting this protein family.
- 24 April 2025
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 65 (9) , 4630-4642
Unveiling G-Protein-Coupled Receptor Conformational Dynamics via Metadynamics Simulations and Markov State Models
The dynamic character of G-protein-coupled receptors (GPCRs) is essential in their functionality as signal transducers. However, the molecular details of how ligands affect this conformational repertoire to steer intracellular signaling pathways remain elusive. To address this question, we present a generally applicable protocol that combines metadynamics simulations and Markov state modeling to compute the free energy landscape of the growth hormone secretagogue receptor (GHSR-1a), a prototypical class A GPCR, in its apo state and bound to pharmacologically distinct ligands. Consistent with the current multistate model of GPCR activity, we found that GHSR-1a populates multiple metastable states whose energies and transition probabilities change depending on the bound ligand. We identified intermediate states that have not yet been described by experimental structures and shed light on the molecular differences between basal and agonist-induced GHSR-1a activation. Our results are not only compatible with previously reported experimental data, but they capture the equilibria governing GHSR-1a activation in unprecedented detail. Due to its applicability to all class A GPCRs, our protocol is a valuable tool for the development of pharmaceuticals targeting this protein family.
- Open Access
Unveiling G-Protein-Coupled Receptor Conformational Dynamics via Metadynamics Simulations and Markov State Models
The dynamic character of G-protein-coupled receptors (GPCRs) is essential in their functionality as signal transducers. However, the molecular details of how ligands affect this conformational repertoire to steer intracellular signaling pathways remain elusive. Here, we address this question by modeling the conformational landscape of the growth hormone secretagogue receptor (GHSR-1a), a prototypical peptide-activated class A GPCR, in its apo state and bound to pharmacologically distinct ligands. We present a generally applicable protocol to efficiently explore the conformational space of GHSR-1a that is sensitive to the bound ligand. Combining metadynamics simulations and Markov state modeling, we computed the free energy landscape of GHSR-1a in its apo state and bound to an agonist, antagonist, or inverse agonist, respectively. Consistent with the current multi-state model of GPCR activity, we found that GHSR-1a populates multiple metastable states whose energies and transition probabilities change depending on the bound ligand. Furthermore, our Markov state models (MSM) have revealed two intermediate states that have not yet been described by experimental structures and which we assume to facilitate the binding of extracellular ligands and intracellular protein partners, respectively. Lastly, our MSMs allowed us to shed light on the molecular differences between basal and agonistinduced GHSR-1a activation. Our results are not only compatible with previously reported experimental data, but they capture the equilibria governing GHSR-1a activation in unprecedented detail. Due to its applicability to all class A GPCRs, our protocol is a valuable tool for the development of pharmaceuticals targeting this protein family.
Open AccessUnveiling G-Protein-Coupled Receptor Conformational Dynamics via Metadynamics Simulations and Markov State Models
The dynamic character of G-protein-coupled receptors (GPCRs) is essential in their functionality as signal transducers. However, the molecular details of how ligands affect this conformational repertoire to steer intracellular signaling pathways remain elusive. Here, we address this question by modeling the conformational landscape of the growth hormone secretagogue receptor (GHSR-1a), a prototypical peptide-activated class A GPCR, in its apo state and bound to pharmacologically distinct ligands. We present a generally applicable protocol to efficiently explore the conformational space of GHSR-1a that is sensitive to the bound ligand. Combining metadynamics simulations and Markov state modeling, we computed the free energy landscape of GHSR-1a in its apo state and bound to an agonist, antagonist, or inverse agonist, respectively. Consistent with the current multi-state model of GPCR activity, we found that GHSR-1a populates multiple metastable states whose energies and transition probabilities change depending on the bound ligand. Furthermore, our Markov state models (MSM) have revealed two intermediate states that have not yet been described by experimental structures and which we assume to facilitate the binding of extracellular ligands and intracellular protein partners, respectively. Lastly, our MSMs allowed us to shed light on the molecular differences between basal and agonistinduced GHSR-1a activation. Our results are not only compatible with previously reported experimental data, but they capture the equilibria governing GHSR-1a activation in unprecedented detail. Due to its applicability to all class A GPCRs, our protocol is a valuable tool for the development of pharmaceuticals targeting this protein family.
- Open Access
- 1 June 2023
- Published by Walter de Gruyter GmbH in Journal of Integrative Bioinformatics
- Vol. 20 (2)
Discovering NDM-1 inhibitors using molecular substructure embeddings representations
NDM-1 (New-Delhi-Metallo-β-lactamase-1) is an enzyme developed by bacteria that is implicated in bacteria resistance to almost all known antibiotics. In this study, we deliver a new, curated NDM-1 bioactivities database, along with a set of unifying rules for managing different activity properties and inconsistencies. We define the activity classification problem in terms of Multiple Instance Learning, employing embeddings corresponding to molecular substructures and present an ensemble ranking and classification framework, relaying on a k-fold Cross Validation method employing a per fold hyper-parameter optimization procedure, showing promising generalization ability. The MIL paradigm displayed an improvement up to 45.7 %, in terms of Balanced Accuracy, in comparison to the classical Machine Learning paradigm. Moreover, we investigate different compact molecular representations, based on atomic or bi-atomic substructures. Finally, we scanned the Drugbank for strongly active compounds and we present the top-15 ranked compounds.
- 1 June 2023
- Published by Walter de Gruyter GmbH in Journal of Integrative Bioinformatics
- Vol. 20 (2)
Open AccessDiscovering NDM-1 inhibitors using molecular substructure embeddings representations
NDM-1 (New-Delhi-Metallo-β-lactamase-1) is an enzyme developed by bacteria that is implicated in bacteria resistance to almost all known antibiotics. In this study, we deliver a new, curated NDM-1 bioactivities database, along with a set of unifying rules for managing different activity properties and inconsistencies. We define the activity classification problem in terms of Multiple Instance Learning, employing embeddings corresponding to molecular substructures and present an ensemble ranking and classification framework, relaying on a k-fold Cross Validation method employing a per fold hyper-parameter optimization procedure, showing promising generalization ability. The MIL paradigm displayed an improvement up to 45.7 %, in terms of Balanced Accuracy, in comparison to the classical Machine Learning paradigm. Moreover, we investigate different compact molecular representations, based on atomic or bi-atomic substructures. Finally, we scanned the Drugbank for strongly active compounds and we present the top-15 ranked compounds.
- 20 October 2022
- Published by Springer Nature
- p. 55-66
Multiple Instance Learning Based on Mol2vec Molecular Substructure Embeddings for Discovery of NDM-1 Inhibitors
- 20 October 2022
- Published by Springer Nature
- p. 55-66
Multiple Instance Learning Based on Mol2vec Molecular Substructure Embeddings for Discovery of NDM-1 Inhibitors
- Open Access
- 9 May 2012
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 109 (21) , 8304-8309
Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor
The dynamic character of G protein-coupled receptors is essential to their function. However, the details of how ligands stabilize a particular conformation to selectively activate a signaling pathway and how signaling proteins affect this conformational repertoire remain unclear. Using a prototypical peptide-activated class A G protein-coupled receptor (GPCR), the ghrelin receptor, reconstituted as a monomer into lipid discs and labeled with a fluorescent conformational reporter, we demonstrate that ligand efficacy and functional selectivity are directly related to different receptor conformations. Of importance, our data bring direct evidence that distinct effector proteins affect the conformational landscape of the ghrelin receptor in different ways. Whereas G proteins affect the balance between active and inactive receptor substates in favor of the active state, agonist-induced arrestin recruitment is accompanied by a marked change in the structural features of the receptor that adopt a conformation different from that observed in the absence of arrestin. In contrast to G proteins and arrestins, μ-AP2 has no significant effect on the organization of the transmembrane core of the receptor. Such a modulation of a GPCR conformational landscape by pharmacologically distinct ligands and effectors provides insights into the structural bases that decisively affect ligand efficacy and subsequent biological responses. This is also likely to have major implications for the design of drugs activating specific GPCR-associated signaling pathways.
- 9 May 2012
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 109 (21) , 8304-8309
Open AccessLigands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor
The dynamic character of G protein-coupled receptors is essential to their function. However, the details of how ligands stabilize a particular conformation to selectively activate a signaling pathway and how signaling proteins affect this conformational repertoire remain unclear. Using a prototypical peptide-activated class A G protein-coupled receptor (GPCR), the ghrelin receptor, reconstituted as a monomer into lipid discs and labeled with a fluorescent conformational reporter, we demonstrate that ligand efficacy and functional selectivity are directly related to different receptor conformations. Of importance, our data bring direct evidence that distinct effector proteins affect the conformational landscape of the ghrelin receptor in different ways. Whereas G proteins affect the balance between active and inactive receptor substates in favor of the active state, agonist-induced arrestin recruitment is accompanied by a marked change in the structural features of the receptor that adopt a conformation different from that observed in the absence of arrestin. In contrast to G proteins and arrestins, μ-AP2 has no significant effect on the organization of the transmembrane core of the receptor. Such a modulation of a GPCR conformational landscape by pharmacologically distinct ligands and effectors provides insights into the structural bases that decisively affect ligand efficacy and subsequent biological responses. This is also likely to have major implications for the design of drugs activating specific GPCR-associated signaling pathways.